Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA

被引：52

作者：

Risitano, Antonio Maria ^{[1
]}

Selleri, Carmine ^{[1
]}

Serio, Bianca ^{[1
]}

Torelli, Giovanni Fernando ^{[2
]}

Kulagin, Alexander ^{[3
]}

Maury, Sebastien ^{[4
]}

Halter, Joerg ^{[5
]}

Gupta, Vikas ^{[6
]}

Bacigalupo, Andrea ^{[7
]}

Socie, Gerard ^{[8
]}

Tichelli, Andre ^{[5
]}

Schrezenmeier, Hubert ^{[9
]}

Marsh, Judith ^{[10
]}

Passweg, Jakob ^{[11
]}

Rotoli, Bruno ^{[1
]}

机构：

[1] Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy

[2] Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, Rome, Italy

[3] Russian Acad Med Sci, Inst Clin Immunol, Siberian Branch, Novosibirsk, Russia

[4] CHU Henri Mondor, Serv Hematol Clin, F-94010 Creteil, France

[5] Univ Basel Hosp, CH-4031 Basel, Switzerland

[6] Univ Toronto, Princess Margaret Hosp, Dept Med, Toronto, ON, Canada

[7] Osped San Martino Genova, Dept Haematol, Genoa, Italy

[8] Hop St Louis, Serv Hematol Greffe, Paris, France

[9] Univ Hosp, Inst Clin Transfus Med & Immunogenet, Inst Transfus Med, Ulm, Germany

[10] Kings Coll Hosp London, Dept Haematol Med, London, England

[11] Univ Hosp Geneva, Serv Hematol, Dept Med Interne, Geneva, Switzerland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2010年 / 148卷 / 05期

关键词：

alemtuzumab; aplastic anaemia; pure red cell aplasia; pure white cell aplasia; bone marrow failure; RED-CELL APLASIA; ANTITHYMOCYTE GLOBULIN; REMISSION; CYCLOSPORINE; CAMPATH-1H; THERAPY; LEUKEMIA;

D O I：

10.1111/j.1365-2141.2009.08027.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.

引用

页码：791 / 796

页数：6

共 15 条

[1] Remission induced by Campath-1H for thymoma-associated agranulocytosis
Alvares, CL
Svasti-Salee, D
Rowley, M
Gordon-Smith, EC
Marsh, JCW
[J]. ANNALS OF HEMATOLOGY, 2004, 83 (06) : 398 - 400
[2] Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia
Au, WY
Lam, CCK
Chim, CS
Pang, AWK
Kwong, YL
[J]. LEUKEMIA RESEARCH, 2005, 29 (10) : 1213 - 1215
[3] What is the definition of cure for aplastic anemia?
Camitta, BM
[J]. ACTA HAEMATOLOGICA, 2000, 103 (01) : 16 - 18
[4] Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab
Elter, Thomas
Vehreschild, Janne J.
Gribben, John
Cornely, Oliver A.
Engert, Andreas
Hallek, Michael
[J]. ANNALS OF HEMATOLOGY, 2009, 88 (02) : 121 - 132
[5] Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia
Frickhofen, N
Heimpel, H
Kaltwasser, JP
Schrezenmeier, H
[J]. BLOOD, 2003, 101 (04) : 1236 - 1242
[6] Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders
Gibbs, SDJ
Westerman, DA
McCormack, C
Seymour, JF
Prince, HM
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (01) : 87 - 91
[7] Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia
Gomez-Almaguer, David
Carlos Jaime-Perez, Jose
Garza-Rodriguez, Veronica
Chapa-Rodriguez, Adrian
Tarin-Arzaga, Luz
Luis Herrera-Garza, Jose
Ruiz-Argueelles, Guillermo J.
Lopez-Otero, Avril
Gonzalez-Llano, Oscar
Rodriguez-Romo, Laura
[J]. ANNALS OF HEMATOLOGY, 2010, 89 (03) : 299 - 303
[8] Sustained remission of severe resistant autoimmune neutropenia with Campath-1H
Killick, SB
Marsh, JCW
Hale, G
Waldmann, H
Kelly, SJ
GordonSmith, EC
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (02) : 306 - 308
[9] A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome
Kim, Hawk
Min, Young Joo
Baek, Jin Ho
Shin, Su Jin
Lee, Eun-Hee
Noh, Eul-Kyu
Kim, Mee-Young
Park, Jae-Hoo
[J]. LEUKEMIA RESEARCH, 2009, 33 (02) : 222 - 231
[10] Maciejewski Jaroslaw P, 2005, Hematology Am Soc Hematol Educ Program, P110, DOI 10.1182/asheducation-2005.1.110

← 1 2 →